SANGAMO THERAPEUTICS, INC (SGMO)
About SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS INC
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $39.6M
- Net income
- -$122.9M
- Total assets
- $59.7M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Sangamo Therapeutics, Inc (SGMO) Stock Price
- Reported a net loss of $122.9M in FY2025.
- Trading 91% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SANGAMO THERAPEUTICS, INC.
Write a review
News about SANGAMO THERAPEUTICS, INC
News & sentiment via Polygon.io
Sangamo Therapeutics, Inc: frequently asked questions
Is Sangamo Therapeutics, Inc an American company?
Sangamo Therapeutics, Inc is a US-based company headquartered in Richmond, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Sangamo Therapeutics, Inc headquartered?
Sangamo Therapeutics, Inc is headquartered in Richmond, California, United States.
Is Sangamo Therapeutics, Inc publicly traded?
Yes — Sangamo Therapeutics, Inc is a publicly traded company. Its stock trades under the ticker symbol SGMO on the OTC.
What does Sangamo Therapeutics, Inc do?
Sangamo Therapeutics, Inc is an American Pharmaceuticals company in the Health & Beauty sector.